Search results
Janssen-Cilag seeks expanded EMA approval for TREMFYA
Pharmaceutical Technology via Yahoo Finance· 5 days agoGuselkumab has been approved in the EU to treat moderate to severe plaque psoriasis in adults who...
FDA OKs High-Concentration of Adalimumab Biosimilar Cyltezo
Medscape· 5 days agoUnlike the low-concentration formulation of adalimumab-adbm, launched July 1, 2023, this high-concentration version has not yet been granted an interchangeability designation.
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First...
Morningstar· 7 days agoAlvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. ...
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
Zacks via Yahoo Finance· 4 days agoTremfya is presently approved to treat certain patients with plaque psoriasis and active psoriatic ...
Citizens Business Bank Sells 329 Shares of Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 1 day agoCitizens Business Bank lowered its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 8.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities ...
653 Shares in Johnson & Johnson (NYSE:JNJ) Acquired by DiNuzzo Private Wealth Inc.
ETF DAILY NEWS· 23 hours agoDiNuzzo Private Wealth Inc. purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities ...
Epic Trust Investment Advisors LLC Has $282,000 Stock Position in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 2 days agoEpic Trust Investment Advisors LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 26.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC ...
Russell Investments Group Ltd. Has $283.28 Million Stock Position in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 5 days agoRussell Investments Group Ltd. lowered its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 5.2% during the fourth quarter, according to the company in its most recent filing with the ...